Revance price target raised to $40 from $37 at Barclays

Barclays analyst Balaji Prasad raised the firm’s price target on Revance to $40 from $37 and keeps an Overweight rating on the shares. The company’s 2023 guidance was "understandably missing" as market dynamics, including buying patterns and usage trends, are still evolving in this early stage for Daxxify, with commercial launch set for late Q1, the analyst tells investors in a research note. The analyst views the stock’s risk/reward as compelling.